Home › Funds › Douglas Lane & Associates, LLC › MRNA
Douglas Lane & Associates, LLC position in MRNA
MODERNA INC · Health Care
Douglas Lane & Associates, LLC reported holding 1,160,945 shares of MRNA (MODERNA INC) in its Q3 2026 13F filing — a position valued at US$223.6M, representing 3.00% of its reported portfolio and ranking #3 among its reported holdings. Douglas Lane & Associates, LLC has disclosed MRNA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR
How Douglas Lane & Associates, LLC's MRNA position evolved
Douglas Lane & Associates, LLC first disclosed a stake in MRNA in Q3 2023 at 355,177 shares (US$36.7M). The position peaked in Q3 2026 at 1,160,945 shares, worth US$223.6M. Across 13 filings, Douglas Lane & Associates, LLC increased the stake 10 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,160,945 shares valued at US$223.6M — a reduction of -182,534 shares quarter over quarter.. Notable position changes include a 63% increase in Q4 2024 (shares fell 32% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 355.18K | $36.69M | New |
| Q4 2023 | 336.14K | $33.43M | Reduce |
| Q1 2024 | 393.04K | $41.88M | Add |
| Q2 2024 | 404.20K | $48.00M | Add |
| Q3 2024 | 475.09K | $31.75M | Add |
| Q4 2024 | 773.80K | $32.17M | Add |
| Q1 2025 | 873.52K | $24.76M | Add |
| Q2 2025 | 930.16K | $25.66M | Add |
| Q3 2025 | 1.13M | $29.15M | Add |
| Q4 2025 | 1.29M | $38.09M | Add |
| Q1 2026 | 1.31M | $66.62M | Add |
| Q2 2026 | 1.34M | $94.08M | Add |
| Q3 2026 | 1.16M | $223.56M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MRNA and 13F data
MRNA (MODERNA INC) is a Health Care company. 36 other funds we track also report a position in MRNA — the largest reported positions include Baillie Gifford & Co (US$1.28B), Theleme Partners LLP (US$564.3M), BANQUE PICTET & CIE SA (US$414.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MRNA
- Baillie Gifford & Co 18.21M sh · $1.28B · Q2 2026
- Theleme Partners LLP 8.06M sh · $564.27M · Q2 2026
- BANQUE PICTET & CIE SA 2.15M sh · $414.27M · Q3 2026
- Flagship Pioneering, LLC 4.63M sh · $324.39M · Q2 2026
- Beau Ventures, LLc 1.00M sh · $192.58M · Q3 2026
- Merck & Co., Inc. 2.31M sh · $161.64M · Q2 2026
- Baron Funds 1.99M sh · $139.32M · Q2 2026
- BAMCO INC /NY/ 1.99M sh · $139.32M · Q2 2026
- IMC-Chicago, LLC 1.70M sh · $119.21M · Q2 2026
More on Douglas Lane & Associates, LLC
FAQ
How long has Douglas Lane & Associates, LLC held MRNA?
Douglas Lane & Associates, LLC has disclosed MRNA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Douglas Lane & Associates, LLC's current position in MRNA?
As of Q3 2026, Douglas Lane & Associates, LLC holds 1.16M shares of MRNA (MODERNA INC), valued at $223.56M, representing 3.00% of its reported portfolio and ranking #3.
Has Douglas Lane & Associates, LLC been buying or selling MRNA?
In the latest 13F filing (Q3 2026), Douglas Lane & Associates, LLC reduced its position in MRNA. The position peaked in Q3 2026 at 1.16M shares.
Which other funds hold MRNA?
Other major institutional holders of MRNA include Baillie Gifford & Co, Theleme Partners LLP, BANQUE PICTET & CIE SA, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.